<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897477</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-066</org_study_id>
    <nct_id>NCT04897477</nct_id>
  </id_info>
  <brief_title>Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open Label, Single Arm, Phase I/II in the Combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma&#xD;
&#xD;
      . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine,&#xD;
      Bendamustine and Piamprizumab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: treatment-related adverse events (AEs)</measure>
    <time_frame>6 month</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>6 month</time_frame>
    <description>The ORR is defined as the proportion of patients with a best overall disease response, including complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>6 month</time_frame>
    <description>CR rate assess by investigators per the 2014 Lugano classification rate of subjects achieved complete response in all evaluable subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-hodgkin Lymphoma,B Cell</condition>
  <arm_group>
    <arm_group_label>combination of Azacytidine, Bendamustine and Piamprizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacytidine, Bendamustine and Piamprizumab</intervention_name>
    <description>Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion</description>
    <arm_group_label>combination of Azacytidine, Bendamustine and Piamprizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤80 years&#xD;
&#xD;
          2. Performance status (ECOG) between 0 and 3.&#xD;
&#xD;
          3. Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including the following&#xD;
             types defined by WHO 2016.&#xD;
&#xD;
          4. Refractory disease or relapsed after treatment with ≥2 lines of chemotherapy and&#xD;
             either having failed autologous HSCT or being ineligible for or not consenting to&#xD;
             autologous HSCT; or not suitable for CAR T treatment or resistance, progression or&#xD;
             relapse after CAR T treatment; or CAR T pre-culturing losers can also be enrolled.&#xD;
&#xD;
          5. Adequate organ function.&#xD;
&#xD;
          6. An adequate bone marrow reserve.&#xD;
&#xD;
          7. Measurable or assessable disease according to the&quot;IWG Response Criteria for Malignant&#xD;
             Lymphoma&quot;(Cheson 2014). Patients in complete remission (CR) with no evidence of&#xD;
             disease were not eligible.&#xD;
&#xD;
          8. Informed consent/assent requiring that all patients have the ability to understand and&#xD;
             the willingness to provide written informed consent.&#xD;
&#xD;
          9. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
         10. Patients with definite involvement of the gastrointestinal tract, and patients with&#xD;
             central nervous system (CNS) by PETCT and MRI involvement were allowed to enrolled in&#xD;
             this clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Uncontrolled medical disorders, active bacterial, viral infection or treponema&#xD;
             pallidum infection and so on.&#xD;
&#xD;
          3. Requirement for urgent therapy due to tumor mass effects such as respiratory&#xD;
             obstruction or blood vessel compression.&#xD;
&#xD;
          4. Current or expected need for systemic corticosteroid therapy.&#xD;
&#xD;
          5. Any organ failure.&#xD;
&#xD;
          6. Patients with a second tumor requiring therapy or intervention.&#xD;
&#xD;
          7. Subjects considered unlikely to complete all protocol-required study visits or&#xD;
             procedures, including follow-up visits, or comply with the study requirements for&#xD;
             participation according to the investigator's judgement.&#xD;
&#xD;
          8. Prior organ allograft.&#xD;
&#xD;
          9. Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong D Han, M.D.</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw69@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>C</last_name>
    </contact_backup>
    <investigator>
      <last_name>Weidong Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yajing Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Nie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhiqiang Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuan Tong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miaomiao Bai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fengxia Shi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

